FDA Grants Bristol Myers Approval for First New Schizophrenia Medication in Decades
Schizophrenia, affecting approximately 2.8 million people in the U.S., has traditionally been managed with medications that often come with severe side effects and limited effectiveness, resulting in poor adherence by patients. Recognizing the need for improved treatments, the Food and Drug Administration (FDA) recently approved Bristol Myers Squibb’s (BMS) new drug, Cobenfy. This approval marks […]